Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s ...
LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation ...
BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...
The payment amount for the Nodify CDT test as established by the Medicare Administrative Contractor is $649. "Receiving ADLT status is a major milestone for Biodesix and confirms the clinical value ...
Biodesix (BDSX) announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT blood-based lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback